Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameTouyun Biotech
Stock Code01332
Company Full NameTo be extracted
IndustryIndustrial Goods
Principal Activities主要從事包裝產品的原設備製造及外判製造,主要產品包括鐘錶盒、珠寶盒、眼鏡盒、包裝袋及小袋以及陳列用品。
Listing Date2012-07-12
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港灣仔杜老志道6號群策大廈12樓
Business Address (Hong Kong)香港北角馬寶道28號華匯中心7樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitequalipakhk.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 1.59 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2012-06-28 to 2012-07-04
Global Offering Shares14,375,999 shares
HK Public Offer Shares (Initial)5,750,000 shares (40.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)8,625,999 shares (60.0%)
Offer Ratio~40.0%
Total Shares Post-IPO143,765,993 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 22,857,838

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 441.7M
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +2094%

Valuation & Financials

Market Cap (at Offer Price)HK$ 228,587,929
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約41.5百萬港元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 22,600,000
Listing Expenses / Funds Raised~98.87%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 HKD
Income Statement
Item 200920102011
Revenue 294,671391,052418,660
Cost of sales -237,883-315,720-332,735
Gross profit 56,78875,33285,925
Other income and gains, net 2,3091,4083,564
Selling and distribution expenses -12,612-14,668-14,969
Administrative expenses -24,113-24,976-27,913
Share of associates and JVs -1,004-638-480
Profit before tax 21,84935,51946,421
Income tax expense -2,724-4,091-4,931
Profit for the year 19,12531,42841,490
Profit attributable to owners 16,44227,37837,828
Balance Sheet
Item 200920102011
Cash and cash equivalents 55,28865,33559,798
Trade and bills receivables 38,19352,77045,916
Inventories 34,86843,07939,007
Total current assets 132,021165,582149,723
Total assets 283,524312,122288,933
Total current liabilities 181,913182,991121,422
Total liabilities 182,996184,086122,439
Total equity 100,528128,036166,494
Equity attributable to owners 98,433125,811164,037
Cash Flow Statement
Item 200920102011
Net cash from investing activities -2,410-2,547670
Net cash from financing activities -76,960-24,698-51,386
Net increase in cash -25,69010,047-5,537
Purchase of PP&E -462-2,605-159
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.42
First Day OpenHK$ 1.68
First Day Change-10.69%
First Day Volume17094300.0
First Day Turnover24596500.0
Use of Proceeds
1、約40%將動用作購買及更換機械及設備,以提升本集團的生產效能及能力,據此新購機械及設備預期將使年產能增加約十分之一; 2、約40%將會動用作開拓新業務機會及提高本集團所生產的產品于市場上的知名度; 3、約10%將會動用作提升本集團設計及開發本集團所生產產品的能力,當中包括購置新型計算機硬件及軟件; 4、約10%將會動用作一般營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
海通国际资本有限公司 CE ADQ859
Joint Lead Managers (1)
海通国际证券有限公司 CE AAF806

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman林孝文—
Company Secretary馮佩玲—
No director data available.

Major Shareholders

Major Shareholders & Holdings張先生、興業及Regulator Holdings為控股股東,緊隨完成分派及股份發售後合共持有約49.38%股權,其中興業佔39.72%,Regulator Holdings佔9.66%。
About this page

This page shows Touyun Biotech (01332) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect